Besides the approval of midostaurin added to intensive chemotherapy or the application of gilteritinib in r/r AML with activating FLT3 mutations, combination treatment of elderly AML patients with HMA and either the BCL-2 inhibitor venetoclax or with ivosidenib in IDH1-mutated AML has contributed to an improved outcome of AML patients [21,22,23,24]. This evidence concerns the gene FLT3 and acute myeloid leukemia.